Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16839800 | 0.87 | KDM4E (0.52) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL10011061 | 0.86 | MEN1 (0.60) | MEN1KMT2AALDH1A1KDM4ECHRM2 | |
| SCHEMBL9832247 | 0.86 | SMN1; SMN2 (0.50) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL16839828 | 0.85 | CETP (0.51) | MEN1KMT2AALDH1A1KDM4ECHRM2 | |
| SCHEMBL9830685 | 0.85 | LTA4H (0.49) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9832496 | 0.83 | KDM4E (0.58) | MEN1KMT2AALDH1A1KDM4ECHRM2 | |
| SCHEMBL3200125 | 0.83 | MEN1 (0.68) | MEN1KMT2AALDH1A1KDM4ECHRM2 | |
| SCHEMBL16839753 | 0.83 | CHRM2 (0.54) | MEN1KMT2AALDH1A1KDM4ECHRM2 | |
| SCHEMBL5939725 | 0.83 | SCN8A (0.52) | MEN1KMT2ASCN8AEPHX2 | |
| SCHEMBL29676705 | 0.83 | CYP1A2 (0.55) | MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0449989-A1 | 6,7 DIHYDROPYRROLO 3,4-c] PYRIDO 2,3-d] PYRIMIDINE DERIVATIVES | Sloan-Kettering Institute For Cancer Research (US) | 1991-10-09 | — | — | EP | claimed |
| WO-1990007496-A1 | 6,7 DIHYDROPYRROLO[3,4-c] PYRIDO[2,3-d] PYRIMIDINE DERIVATIVES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1990-07-12 | — | — | WO | claimed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| EP-0449989-A1 | 6,7 DIHYDROPYRROLO 3,4-c] PYRIDO 2,3-d] PYRIMIDINE DERIVATIVES | Sloan-Kettering Institute For Cancer Research (US) | 1991-10-09 | — | — | EP | disclosed |
| WO-1990007496-A1 | 6,7 DIHYDROPYRROLO[3,4-c] PYRIDO[2,3-d] PYRIMIDINE DERIVATIVES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1990-07-12 | — | — | WO | disclosed |
| US-4925939-A | 6,7-dihydropyrrol[3,4-c]pyrido[2,3-d]pyrimidine derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | MEN1 2104/4885KMT2A 1931/4885ALDH1A1 4776/4885 |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | MEN1 1627/4885KMT2A 64/4885ALDH1A1 2293/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | MEN1 2104/4885KMT2A 1931/4885ALDH1A1 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.